EP1608661A2 - Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds - Google Patents

Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds

Info

Publication number
EP1608661A2
EP1608661A2 EP04722335A EP04722335A EP1608661A2 EP 1608661 A2 EP1608661 A2 EP 1608661A2 EP 04722335 A EP04722335 A EP 04722335A EP 04722335 A EP04722335 A EP 04722335A EP 1608661 A2 EP1608661 A2 EP 1608661A2
Authority
EP
European Patent Office
Prior art keywords
formula
alkyl
group
methyl
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04722335A
Other languages
German (de)
French (fr)
Inventor
Yatendra Kumar
Neera Tewari
Shailendra Kumar Singh
Bishwa Prakash Rai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1608661A2 publication Critical patent/EP1608661A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02—Preparation
    • C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C07D501/06—Acylation of 7-aminocephalosporanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36—Methylene radicals, substituted by sulfur atoms

Definitions

  • the field of the invention relates to pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
  • the invention also relates to processes for the preparation of pure 7- amino (p-hydroxyphenylglycyl) cephem compounds and pharmaceutical compositions that include the pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
  • 7- amino (p-hydroxyphenylglycyl) cephem compounds such as cefprozil, cefadroxil and cefatrizine are generally prepared by reacting a cephem derivative with a reactive derivative, such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
  • a reactive derivative such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
  • British Patent GB 1,240,687 discloses a process involving reacting N-protected 4- hydroxyplienylglycine with ethyl chloroformate to obtain a carbonate derivative which is acylated with a cephem compound.
  • this method gives a product of low purity.
  • a major impurity formed in such a process has the structure of Formula A,
  • R is a group commonly used at the 3-position in cephalosporins, for example, methyl, 1-propenyl and l,2,3-triazol-5-yl tbiornethyl.
  • the present invention provides a process which results in pure 7- amino (p- hydroxyphenylglycyl) cephem compounds.
  • the process of the present invention avoids purification by tedious and cumbersome processes.
  • the process of the present invention reduces the impurity content of the final product, eliminates the costly and time- consuming purification steps.
  • R is a group commonly used at the 3-position in cephalosporins and may include C 1 6 alkyl, C 2 6 alkenyl, C 2 _ 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . h particular, it may include methyl, 1- propenyl and l,2,3-triazol-5-yl thiomethyl.
  • compositions and dosage forms containing a therapeutically effective amount of the cephem compounds of Formula I and which may also contain pharmaceutically acceptable carriers, excipients or diluents which are useful for the treatment of bacterial infections.
  • a method of treating bacterial infections comprising administering to a mammal in need thereof, a therapeutically effective amount of cephem compounds of Formula I as described above.
  • R is a group commonly used at the 3 -position in cephalosporins and includes C l g alkyl, C 2 6 alkenyl, C 2 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 _ 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . hi particular, it includes methyl, 1- propenyl and l,2,3-triazol-5-yl tl iomethyl.
  • the process comprising:
  • R' is C 1-4 alkyl and M + is an alkali metal cation
  • R is C 1 6 alkyl, C,_ 6 alkenyl, C 2 _ 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl,
  • the preparation of the mixed anhydride is carried out in the presence of a small amount of an acid to minimize the formation of impurity of Formula B, in the step ii) reaction,
  • R is a group commonly used at the 3-position in cephalosporins, and includes C. 6 alkyl, C 2 6 alkenyl, C 2 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl.
  • the process is useful for the preparation of a wide variety of 7- amino(p- hydroxyphenylglycyl) -cephalosporins, for example, cefatrizine, cefadroxil, or cefprozil, in good yield and purity.
  • Examples of Dane salts of Formula III include sodium or potassium D-N-(l- methoxycarbonylpropen-2-yl)amino-p-hydroxyphenyl- acetate, and sodium or potassium D-N-(l-ethoxycarbonyl- propen-2-yl)-amino-p-hydroxyphenylacetate.
  • Examples of alkyl chloro formates include ethyl chloroformate and methyl chloroformate.
  • Examples of amines present as a catalyst for mixed carboxylic acid anhydride formation include N-methyl morpholine, N,N-dimethyl benzyl amine, pyridine, picoline, and lutidine.
  • the mixed anhydride may be prepared in one or more solvents, including, for example, halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon, amide and mixtures thereof.
  • chlorinated hydrocarbons include dichoromethane and dichloroethylene;
  • ketones include acetone and methyl isobutyl ketone;
  • ester include ethyl acetate and isopropylacetate;
  • Examples of ether include tetrahydrofuran and dioxane; a nitrile includes acetonitrile;
  • aromatic hydrocarbon include toluene.
  • a suitable co-solvent may be used with a solvent, for example amide.
  • a suitable amide includes one or more of formamide, acetamide, N,N- dimethyl formamide, N-methylacetamide, N,N-dimethylacetamide and N- methylpyrrolidone. Mixtures of all of these solvents are also contemplated.
  • the formation of the mixed carboxylic acid anhydride may be carried out at temperatures, from about -80°C to about 50°C, or from about -50°C to about 5°C.
  • step i) is generally obtained as a solution or a suspension of the mixed carboxylic acid anhydride, and can be further used as such. If desired, this anhydride may be maintained at from about -60°C to about -20°C.
  • the 7-amino-ceph-3-em-4-carboxylic acid of Formula II maybe silylated with silylation agents in a solvent inert under the reaction conditions.
  • silylation agents include mono- or bissilylated amides, such as N,0-bis-(trimethylsilyl)acetamide (BSA), N-methyl-N-trimethylsilyl-acetamide (MSA); silylated ureas, such as N,N'-bis- (trimethylsilyl)-urea (BSU); or silazanes, such as 1 1 3,3,3- hexamethyldisilazane (HMDS), in combination with a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such as triethylamine, tert.octylamine.
  • a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such
  • the solvents used for mixed anhydride preparation above may be used for silylation of the 7-amino-ceph-3-em-4-carboxylic acid, and also for the step ii) reaction.
  • the reaction temperatures for the step ii) may be from about -60°C to room temperature or from about -40 ° C to about -10°C.
  • the reaction mixture of the step ii) may be worked up in a conventional manner.
  • the substituted vinyl group may be split by hydrolysis in aqueous acid.
  • the final product may be isolated in a conventional manner, for example by adjusting the pH of the reaction mixture.
  • the product of Formula I can be obtained in a very high purity, for example above 98%.
  • the 7-amino-ceph-3-em-4-carboxylic acid of Formula II may be prepared in accordance with any of the known methods (see U.S. Patent Nos. 3,867,380; 3 489,752 and 4,520,022).
  • the Dane salt of Formula III may be obtained from commercial sources or prepared by methods well known in the art.
  • compounds of Formula I having less than 0.5% by weight of the impurity of Formula B can be obtained.
  • compounds of Formula I having less than 0.1% by weight of the impurity of Formula B, or less than 0.05% can be obtained.
  • the resulting cephem compounds of Formula I may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. hi these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients.
  • compositions include dosage forms suitable for oral and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration.
  • the oral dosage forms may include solid dosage forms, like powder, tablets, capsules, as well as liquid suspensions.
  • Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like.
  • the suspension of silylated 7-APCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes.
  • a mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C.
  • the aqueous layer was diluted with dimethylformamide(700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution.
  • the mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered.
  • the solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 98g of cefprozil as dimethyl formamide (1.5 mole) solvate.
  • the suspension of silylated 7-ADCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes.
  • a mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C.
  • the aqueous layer was diluted with dimethylformamide (700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution.
  • the mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered.
  • the solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 105g of cefadroxil as dimethyl formamide (1.5 mole) solvate.
  • cefadroxil dimethyl formamide solvate was converted to white crystalline solid cefadroxil monohydrate by the procedure reported in U.S. Patent No. 4,504,657.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The invention relates to pure 7- amino (p-hydroxyphenylglycyl) cephem compounds. The invention also relates to processes for the preparation of pure 7- amino (p-hydroxyphenylglycyl) cephem compounds and pharmaceutical compositions that include the pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.

Description

PROCESS FOR THE PREPARATION OF 7-AMINO (p- HYDROXYPHENYLGLYCYL) CEPHEM COMPOUNDS
Field of the Invention
The field of the invention relates to pure 7- amino (p-hydroxyphenylglycyl) cephem compounds. The invention also relates to processes for the preparation of pure 7- amino (p-hydroxyphenylglycyl) cephem compounds and pharmaceutical compositions that include the pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
Background of the Invention
7- amino (p-hydroxyphenylglycyl) cephem compounds such as cefprozil, cefadroxil and cefatrizine are generally prepared by reacting a cephem derivative with a reactive derivative, such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
British Patent GB 1,240,687 discloses a process involving reacting N-protected 4- hydroxyplienylglycine with ethyl chloroformate to obtain a carbonate derivative which is acylated with a cephem compound. However, this method gives a product of low purity. A major impurity formed in such a process has the structure of Formula A,
FORMULA A
wherein R is a group commonly used at the 3-position in cephalosporins, for example, methyl, 1-propenyl and l,2,3-triazol-5-yl tbiornethyl.
It was observed that this impurity is formed by reaction of ethyl chloroformate with the phenolic hydroxyl group under basic reaction conditions employed.
Thus, the present invention provides a process which results in pure 7- amino (p- hydroxyphenylglycyl) cephem compounds. The process of the present invention avoids purification by tedious and cumbersome processes. The process of the present invention reduces the impurity content of the final product, eliminates the costly and time- consuming purification steps.
Summary of the Invention
In one general aspect there are provided pure cephem compounds of Formula I,
FORMULA I
wherein R is a group commonly used at the 3-position in cephalosporins and may include C1 6 alkyl, C2 6 alkenyl, C2_6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . h particular, it may include methyl, 1- propenyl and l,2,3-triazol-5-yl thiomethyl.
i another general aspect there is provided a process for the preparation of cephem compounds of Formula I.
In another aspect there is provided a pharmaceutical composition and dosage forms containing a therapeutically effective amount of the cephem compounds of Formula I and which may also contain pharmaceutically acceptable carriers, excipients or diluents which are useful for the treatment of bacterial infections.
In another aspect there is provided a method of treating bacterial infections comprising administering to a mammal in need thereof, a therapeutically effective amount of cephem compounds of Formula I as described above.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. Detailed Description of the Invention
The inventors have developed a process for the preparation of certain cephem compounds of Formula I,
FORMULA I
wherein R is a group commonly used at the 3 -position in cephalosporins and includes Cl g alkyl, C2 6 alkenyl, C2 6 alkynyl, C2 6 alkadienyl, cyclic C3_6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . hi particular, it includes methyl, 1- propenyl and l,2,3-triazol-5-yl tl iomethyl. The process comprising:
(i) . reacting a Dane salt of Formula III,
FORMULA III
wherein R' is C1-4 alkyl and M+is an alkali metal cation,
with a lower alkyl chloroformate in the presence of an amine, and an acid, to obtain a mixed carboxylic acid anhydride of Formula IN, and
HO— (( )) — CH— COOCOOAIkyl
I
ΝH I H3C— C=CHCOOR'
FORMULA IV (ii) reacting the mixed carboxylic acid anhydride with a silylated derivative of the 7- amino-ceph-3-em-4-carboxylic acid of Formula II,
FORMULA II
wherein R is C1 6 alkyl, C,_6 alkenyl, C2_6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl,
to obtain the cephem compound of Formula I.
hi general, the preparation of the mixed anhydride is carried out in the presence of a small amount of an acid to minimize the formation of impurity of Formula B, in the step ii) reaction,
FORMULA B
wherein R is a group commonly used at the 3-position in cephalosporins, and includes C. 6 alkyl, C2 6 alkenyl, C2 6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl.
The process is useful for the preparation of a wide variety of 7- amino(p- hydroxyphenylglycyl) -cephalosporins, for example, cefatrizine, cefadroxil, or cefprozil, in good yield and purity.
Examples of Dane salts of Formula III include sodium or potassium D-N-(l- methoxycarbonylpropen-2-yl)amino-p-hydroxyphenyl- acetate, and sodium or potassium D-N-(l-ethoxycarbonyl- propen-2-yl)-amino-p-hydroxyphenylacetate. Examples of alkyl chloro formates include ethyl chloroformate and methyl chloroformate.
Examples of amines present as a catalyst for mixed carboxylic acid anhydride formation include N-methyl morpholine, N,N-dimethyl benzyl amine, pyridine, picoline, and lutidine.
The mixed anhydride may be prepared in one or more solvents, including, for example, halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon, amide and mixtures thereof. Examples of chlorinated hydrocarbons include dichoromethane and dichloroethylene; Examples of ketones include acetone and methyl isobutyl ketone; Examples of ester include ethyl acetate and isopropylacetate; Examples of ether include tetrahydrofuran and dioxane; a nitrile includes acetonitrile; Examples of aromatic hydrocarbon include toluene. A suitable co-solvent may be used with a solvent, for example amide. A suitable amide includes one or more of formamide, acetamide, N,N- dimethyl formamide, N-methylacetamide, N,N-dimethylacetamide and N- methylpyrrolidone. Mixtures of all of these solvents are also contemplated.
The formation of the mixed carboxylic acid anhydride may be carried out at temperatures, from about -80°C to about 50°C, or from about -50°C to about 5°C.
The product of step i) is generally obtained as a solution or a suspension of the mixed carboxylic acid anhydride, and can be further used as such. If desired, this anhydride may be maintained at from about -60°C to about -20°C.
The 7-amino-ceph-3-em-4-carboxylic acid of Formula II maybe silylated with silylation agents in a solvent inert under the reaction conditions. Examples of silylation agents include mono- or bissilylated amides, such as N,0-bis-(trimethylsilyl)acetamide (BSA), N-methyl-N-trimethylsilyl-acetamide (MSA); silylated ureas, such as N,N'-bis- (trimethylsilyl)-urea (BSU); or silazanes, such as 1 1 3,3,3- hexamethyldisilazane (HMDS), in combination with a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such as triethylamine, tert.octylamine.
The solvents used for mixed anhydride preparation above may be used for silylation of the 7-amino-ceph-3-em-4-carboxylic acid, and also for the step ii) reaction. The reaction temperatures for the step ii) may be from about -60°C to room temperature or from about -40 ° C to about -10°C.
The reaction mixture of the step ii) may be worked up in a conventional manner. The substituted vinyl group may be split by hydrolysis in aqueous acid.
The final product may be isolated in a conventional manner, for example by adjusting the pH of the reaction mixture. The product of Formula I can be obtained in a very high purity, for example above 98%.
The 7-amino-ceph-3-em-4-carboxylic acid of Formula II may be prepared in accordance with any of the known methods (see U.S. Patent Nos. 3,867,380; 3 489,752 and 4,520,022).
The Dane salt of Formula III may be obtained from commercial sources or prepared by methods well known in the art.
Thus, compounds of Formula I having less than 0.5% by weight of the impurity of Formula B can be obtained. In particular, compounds of Formula I having less than 0.1% by weight of the impurity of Formula B, or less than 0.05% can be obtained.
The resulting cephem compounds of Formula I may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. hi these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients.
The compositions include dosage forms suitable for oral and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration. The oral dosage forms may include solid dosage forms, like powder, tablets, capsules, as well as liquid suspensions. Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like.
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and are not intended to limit the scope of the invention. Although the examples are directed to the cefprozil and cefdroxil, the principles described in these examples can be applied to other cephem compounds. Example 1
Cefprozil
7-amino-3-(propen-l-yl)-3-cephem-4-carboxylic acid (7-APCA, 50g) was added to methylene chloride (300ml). 1,1,3,3-hexamethylsilazane (25g), chlorotrimethylsilane (17.5g) and imidazole (0.5g) were added. The reaction mixture was refluxed for 3-4 hours and then cooled to 0 to 5°C.
Potassium (D)-N-(l-methyoxycarbonyl-propen-2-yl)-o;-ammo-p-hydroxyphenyl acetate (Dane salt, 71g) was added to methylene chloride (300ml) and dimethylformamide (200ml) and stirred at -40 to -45°C. N-methylmorpholine (0.42g) and methanesulfonic acid (1.0 g) were added followed by ethylchloroformate (28.2g) and stirred for about 90 minutes at -35 to -40°C. It was then cooled to -65 to -70°C.
The suspension of silylated 7-APCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes. A mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C. The aqueous layer was diluted with dimethylformamide(700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution. The mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered. The solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 98g of cefprozil as dimethyl formamide (1.5 mole) solvate.
Moisture content by KF = 0.25%; HPLC purity =99.58%; DMF content (by GC) = 18.2%
Impurity of formula B (R = 1-propenyl, Alkyl = ethyl) = 0.05% (by HPLC)
Above cefprozil dimethyl formamide solvate was converted to crystalline cefprozil monohydrate by the procedure reported in U.S. Patent No. 4,694,079. Example 2
Cefadroxil
7-amino-3-desacetoxy-3-cephem-4-carboxylic acid (7-ADCA, 50g) was added to methylene chloride (300ml). 1,1,3,3-hexamethylsilazane (26g), chlorotrimethylsilane (18.7g) and imidazole (0.5g) were added. The reaction mixture was refluxed for 3-4 hours and then cooled to 0 to 5°C.
Potassium (D)-N-( 1 -methyoxycarbonyl-propen-2-yl)-α-amino-p-hydiOxyphenyl acetate (Dane salt, 79g) was added to methylene chloride (300ml) and dimethylformamide (200ml) and stirred at -40 to -45°C. N-methylmorpholine (0.47g) and methanesulfonic acid (1.12 g) were added followed by ethylchloroformate (29.5g) and stirred for about 90 minutes at -35 to -40°C. It was then cooled to -65 to -70°C.
The suspension of silylated 7-ADCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes. A mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C. The aqueous layer was diluted with dimethylformamide (700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution. The mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered. The solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 105g of cefadroxil as dimethyl formamide (1.5 mole) solvate.
Moisture content by KF = 0.48%; HPLC purity =99.24%; DMF content (by GC) = 22.8%
Impurity of formula B (R = methyl, Alkyl = ethyl) = 0.08% (by HPLC)
Above cefadroxil dimethyl formamide solvate was converted to white crystalline solid cefadroxil monohydrate by the procedure reported in U.S. Patent No. 4,504,657.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Claims

WE CLAIM:
1. A process for the production of a cephem compound of Formula I,
FORMULA I
wherein R is C1 6 alkyl, C2_6 alkenyl, C2_6 allcynyl, C2 g alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl, the process comprising:
i) reacting a Dane salt of Formula III,
FORMULA III
wherein R' is Cχ 4 alkyl and M+ is an alkali metal cation, with a lower alkyl chloroformate in the presence of an amine, and an acid, to obtain a mixed carboxylic acid anhydride of Formula IN,
FORMULA IN
wherein R' is as defined above and alkyl is methyl or ethyl, and
ii) reacting the mixed carboxylic acid anhydride with a silylated derivative of the 7-amino-ceph-3-em-4-carboxylic acid of Formula II, FORMULA E
wherein R is as defined above,
to obtain the cephem compound of Formula I. 2. The process of claim 1, wherein the R group is methyl, 1-propenyl and 1,
2,3- triazol-5-yl thiomethyl.
3. The process of claim 1, wherein the Dane salt used in step i) is selected from the group consisting of sodium or potassium D-N-( 1 -methoxycarbonylpropen-2-yl)ammo-p- hydroxyphenyl- acetate, and sodium or potassium D-N-(l-ethoxycarbonyl- propen-2-yl)- amino-p-hydroxyphenylacetate.
4. The process of claim 1, wherein the alkyl chloro formates is ethyl chloroformate or methyl chloroformate.
5. The process of claim 1, wherein the amine is selected from the group consisting of N-methyl morpholine, N,N-dimethyl benzyl amine, pyridine, picoline, and lutidine.
6. The process of claim 1, wherein step i) is performed in a solvent.
7. The process of claim 6, wherein the solvent comprises one or more of a halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon or mixtures thereof.
8. The process of claim 7, wherein the solvent is selected from the group consisting of dichloromethane, dichloroethylene, acetone, methyl isobutyl ketone, ethyl acetate, isopropylacetate, tetrahydrofuran, dioxane, acetonitrile and toluene.
9. The process of claim 1, wherein the step i) is carried out at temperature from about -80°C to about 50°C.
10. The process of claim 9, wherein the step i) is carried out at temperature from about -50°C to about 5°C.
11. The process of claim 6, wherein a co-solvent is used.
12. The process of claim 11, wherein the co-solvent is selected from the group consisting of formamide, acetamide, N,N-dimethyl formamide, N-methylacetamide, N,N- dimethylacetamide, and N-methylpyrrolidone.
13. The process of claim 1, wherein the step ii) is performed in a solvent.
14. The process of claim 13, wherein the solvent comprises one or more of halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon, or mixtures thereof.
15. The process of claim 14, wherein the solvent is selected from the group consisting of dichloromethane, dichloroethylene, acetone, methyl isobutyl ketone, ethyl acetate, isopropylacetate, tetrahydrofuran, dioxane, acetonitrile and toluene.
16. The process of claim 1, wherein the step ii) is carried out at temperatures from about -60°C to about 25°C.
17. The process of claim 16, wherein the step ii) is carried out at temperatures from about -40°C to about - 10°C.
18. The process of claim 1, wherein the silylation of the 7-amino-ceph-3-em-4- carboxylic acid of Formula II is carried out with a silylation agent selected from the group consisting of mono- or bissilylated amides, silylated ureas, and silazanes, in combination with a halosilane or an amine.
19. The process of claim 18, wherein the silylation agent is selected from the group consisting of N,0-bis-(trimethylsilyl)acetamide (BSA), N-methyl-N-trimethylsilyl- acetamide (MSA), N,N'-bis-(trimethylsilyl)-urea (BSU), and 1 1 3,3,3- hexamethyldisilazane (HMDS),
20. The process of claim 18, wherein the halosilane is trimethylchlorsilane and dimethyldichlorosilane.
21. The process of claim 18, wherein the amine comprises one or more of triethylamine, and tert.octylamine.
22. Compounds of Formula I,
FORMULA I
wherein R is Cl g alkyl, C2 g alkenyl, C2 6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl,, having less than 0.5% by weight of the impurity of Formula B,
FORMULA B
wherein R is as defined above.
23. The compound of claim 22, wherein the R group is methyl, 1-propenyl and 1,2,3- triazol-5-yl thiomethyl.
24. The compound of claim 22, wherein the impurity of Formula B is less than 0.1 % by weight.
25. The compound of claim 24, wherein the impurity of Formula B is less than 0.05% by weight.
26. The compound of claim 22 or 23, wherein the alkyl group in the impurity of Formula B is methyl or ethyl.
27. A pharmaceutical composition comprising the compound of claim 22 or 23 optionally together with pharmaceutically acceptable carriers, excipients or diluents.
28. A pharmaceutically acceptable composition comprising a pharmaceutically acceptable effective amount of a compound according to claim 22 or 23 with a pharmaceutically acceptable carrier for treating bacterial infections.
EP04722335A 2003-03-21 2004-03-22 Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds Withdrawn EP1608661A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INDE03532003 2003-03-21
IN353DE2003 2003-03-21
PCT/IB2004/000850 WO2004083172A2 (en) 2003-03-21 2004-03-22 Process for the preparation of 7-amino (p-hydroxyphenylglyclyamido) cephem compounds

Publications (1)

Publication Number Publication Date
EP1608661A2 true EP1608661A2 (en) 2005-12-28

Family

ID=33017825

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04722335A Withdrawn EP1608661A2 (en) 2003-03-21 2004-03-22 Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds

Country Status (3)

Country Link
EP (1) EP1608661A2 (en)
CA (1) CA2519853A1 (en)
WO (1) WO2004083172A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1809638T3 (en) * 2004-11-01 2010-07-30 Hetero Drugs Ltd A novel process for preparation of cefprozil intermediate
CN102408438B (en) * 2010-09-26 2015-01-07 石药集团中奇制药技术（石家庄）有限公司 Preparation method of cefprozil monohydrate
CN102443013B (en) * 2010-10-10 2014-09-17 石药集团中奇制药技术（石家庄）有限公司 Method for preparing cefprozil dimethyl formamide solvate
CN102911187B (en) * 2012-10-11 2015-03-11 南通康鑫药业有限公司 Recovery method of cefprozil
CN112694487B (en) * 2020-12-29 2022-04-22 苏州盛达药业有限公司 Preparation method of cefprozil
CN113533591B (en) * 2021-06-18 2022-08-23 山东罗欣药业集团恒欣药业有限公司 GC analysis method for benzene and paraldehyde in cefprozil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899394A (en) * 1972-12-26 1975-08-12 Bristol Myers Co Production of antibacterial agents
FR2215939B1 (en) * 1973-01-31 1976-07-02 Roussel Uclaf
GB1505345A (en) * 1974-04-10 1978-03-30 Beecham Group Ltd Cephalosporins
US4148817A (en) * 1976-03-25 1979-04-10 Eli Lilly And Company Process and intermediates for preparing cephalosporin antibiotics
IT1065387B (en) * 1976-12-16 1985-02-25 Dobfar Spa PROCEDURE FOR THE PREPARATION OF CEPHALOSPORINE
KR820001564B1 (en) * 1981-05-09 1982-09-02 동신제약 주식회사 Method for preparing cephalosporin derivative using novel silylating agent
US20040077849A1 (en) * 2002-10-16 2004-04-22 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefadroxil
US6903211B2 (en) * 2002-10-30 2005-06-07 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of 3-propenyl cephalosporin DMF solvate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004083172A2 *

Also Published As

Publication number Publication date
WO2004083172A2 (en) 2004-09-30
CA2519853A1 (en) 2004-09-30
WO2004083172A3 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
US6552186B2 (en) β-lactam production
EP0233271B1 (en) Process for preparing cephalosporin intermediates
EP1068211B1 (en) Process for purification of a cephalosporin derivative
US7427692B2 (en) Process for preparation of 7-[α-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid
EP1608661A2 (en) Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds
WO2002083634A2 (en) Process for the preparation of cefpodoxime acid
US5998610A (en) Silylation process
BG61189B1 (en) Process for the preparation of a cephalosporin antibiotic
RO109652B1 (en) PROCEDURE FOR PREPARING AN ANTIBIOTIC CEFEPIM HYDROCHLORIDE DIHYDROCARORIDE
EP1809638B1 (en) A novel process for preparation of cefprozil intermediate
US4868294A (en) Process for preparing cephalosporin intermediates
WO2005040175A2 (en) Process for the preparation of cephem carboxylic acids
KR920001769B1 (en) A process for preparing chlorocefadroxil monohydrate
JP4616844B2 (en) Production process of intermediates for use in the synthesis of cephalosporin
KR840002046B1 (en) Process for preparing cepharosporins
US20040077849A1 (en) Process for the preparation of cefadroxil
WO2002004463A1 (en) Novel cephalosporin compounds and process for preparing the same
AU2002307885A1 (en) Process for the preparation of cefpodoxime acid
JP2005521692A (en) Novel cephalosporin compound and method for producing the same
MXPA96005773A (en) Cephalosporine compounds and processes for the preparation of mis
HK1034078B (en) Process for purification of a cephalosporin derivative
JPH0322391B2 (en)
JPS6117837B2 (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071002